News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
805,714 Results
Type
Article (74001)
Company Profile (695)
Press Release (731018)
Section
Business (227380)
Career Advice (3710)
Deals (39290)
Drug Delivery (121)
Drug Development (89158)
Employer Resources (194)
FDA (17755)
Job Trends (17089)
News (387477)
Policy (38711)
Tag
Academia (2974)
Alliances (55755)
Alzheimer's disease (1358)
Approvals (17664)
Artificial intelligence (172)
Bankruptcy (392)
Best Places to Work (12558)
Biotechnology (477)
Breast cancer (198)
Cancer (1422)
Cardiovascular disease (121)
Career advice (3158)
Cell therapy (306)
Clinical research (70770)
Collaboration (484)
Compensation (254)
COVID-19 (2813)
C-suite (119)
Data (1397)
Diabetes (181)
Diagnostics (6707)
Earnings (92161)
Employer resources (167)
Events (126202)
Executive appointments (384)
FDA (18421)
Funding (435)
Gene therapy (218)
GLP-1 (709)
Government (5003)
Healthcare (20720)
Infectious disease (2911)
Inflammatory bowel disease (125)
Interviews (724)
IPO (17558)
Job creations (4994)
Job search strategy (2592)
Layoffs (492)
Legal (9860)
Lung cancer (206)
Manufacturing (219)
Medical device (14437)
Medtech (14442)
Mergers & acquisitions (21837)
Metabolic disorders (503)
Neuroscience (1705)
NextGen Class of 2024 (7619)
Non-profit (5065)
Northern California (1682)
Obesity (290)
Opinion (246)
Patents (124)
People (63175)
Pharmaceutical (142)
Phase I (21831)
Phase II (30860)
Phase III (23296)
Pipeline (519)
Postmarket research (3262)
Preclinical (9646)
Radiopharmaceuticals (258)
Rare diseases (283)
Real estate (7138)
Regulatory (25389)
Research institute (2641)
Resumes & cover letters (580)
Southern California (1468)
Startups (4186)
United States (15876)
Vaccines (665)
Weight loss (228)
Date
Today (64)
Last 7 days (718)
Last 30 days (2877)
Last 365 days (37999)
2024 (37065)
2023 (42567)
2022 (53926)
2021 (58725)
2020 (57668)
2019 (51305)
2018 (39086)
2017 (36851)
2016 (37768)
2015 (43759)
2014 (38466)
2013 (34461)
2012 (36372)
2011 (36477)
2010 (35942)
Location
Africa (1190)
Arizona (209)
Asia (48056)
Australia (8274)
California (3902)
Canada (1431)
China (307)
Colorado (179)
Connecticut (191)
Europe (108502)
Florida (530)
Georgia (141)
Illinois (438)
Indiana (237)
Maryland (670)
Massachusetts (3145)
Michigan (190)
Minnesota (311)
New Jersey (1120)
New York (1090)
North Carolina (869)
Northern California (1682)
Ohio (154)
Pennsylvania (929)
South America (1560)
Southern California (1468)
Texas (570)
Utah (112)
Washington State (428)
805,714 Results for "chengdu kanghong pharmaceuticals group co ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioCapital
Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd.
Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.
June 6, 2024
·
3 min read
Press Releases
Lakeside Holding Enters Medical Logistics Sector with Acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd.
November 11, 2024
·
4 min read
Press Releases
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
October 15, 2024
·
3 min read
Press Releases
WORK Medical Technology Group LTD’s Subsidiary, Hangzhou Shanyou, Showcases Products at MEDICA Trade Fair 2024
November 28, 2024
·
4 min read
Press Releases
Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories
December 13, 2024
·
11 min read
Business
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals Inc. today announced that it has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. Ltd. (Torii), to jointly conduct a global pivotal Phase 3 clinical trial of YCANTH® for the treatment of common warts.
May 15, 2024
·
9 min read
Press Releases
Inari Medical Announces Reimbursement Approval for ClotTriever® Thrombectomy System in Japan and New Distribution Partnership with Medikit Co., Ltd.
December 3, 2024
·
4 min read
Drug Development
Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2201 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration
Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced today the first patient dosed in the VAN-2201 multi-center Phase 1 clinical trial evaluating treatment with KH631 for patients with wet Age-related Macular Degeneration (wet AMD).
November 20, 2023
·
5 min read
Press Releases
Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to “BGM”
August 13, 2024
·
2 min read
Meihua International Medical Technologies Co., Ltd. Announces Share Repurchase Program of Up to $3 million
Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.
July 1, 2024
·
5 min read
1 of 80,572
Next
